Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
Top Cited Papers
- 15 July 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (14) , 2689-2696
- https://doi.org/10.1200/jco.2003.12.142
Abstract
Purpose: Somatostatin analogs and interferon alfa control hormone-active/functional neuroendocrine gastroenteropancreatic tumors. In addition to hormonal control, variable degrees of antiproliferative effects for both agents have been reported. Until now, however, no prospective, randomized studies in therapy-naive patients have compared somatostatin analogs or interferon alfa alone with a combination of the two. Methods: Eighty therapy-naive patients with histologically verified neuroendocrine tumor disease (primary localization: foregut, n = 36; midgut, n = 30; hindgut, n = 3; unknown, n = 11; functional, n = 29; nonfunctional, n = 51) were randomly treated either with lanreotide (1 mg three times a day administered subcutaneously [SC]) or interferon alfa (5 × 106 U three times a week SC) or both. All patients had disease progression in the 3 months before study entry, verified with imaging procedures. Results: Twenty-five patients were treated with lanreotide, 27 patients were treated with interferon alfa, and 28 patients were treated with the combination. Partial tumor remission was seen in four patients (one patient who received lanreotide, one patient who received interferon alfa, and two patients who received the combination). During the 12 months of therapy, stable disease was observed in 19 patients (seven patients who received lanreotide, seven patients who received interferon alfa, and five patients who received the combination), whereas tumor progression occurred in 14 of 25 patients (lanreotide), 15 of 27 patients (interferon alfa), and 14 of 28 patients (combination). Side effects leading to an interruption of therapy were more frequent in the combination group than in the monotherapy arms. Conclusion: This prospective, randomized, multicenter study shows for the first time that somatostatin analogs, interferon alfa, or the combination of the two had comparable antiproliferative effects in the treatment of metastatic neuroendocrine gastroenteropancreatic tumors. Response rates were lower compared with those published in previous, nonrandomized studies. The antiproliferative effect of the tested substances was similar for functional and nonfunctional neuroendocrine tumors.Keywords
This publication has 30 references indexed in Scilit:
- Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-a and the combination for therapy of metastatic neuroendocrine gep-tumorsGastroenterology, 2000
- Long-term results of continuous treatment with recombinant interferon-a in patients with metastatic carcinoid tumors???an antiangiogenic effect?Anti-Cancer Drugs, 1996
- Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.Gut, 1996
- Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.Journal of Clinical Investigation, 1994
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal Of Cancer, 1992
- Multiple imputation in health‐are databases: An overview and some applicationsStatistics in Medicine, 1991
- Treatment of Gastrointestinal Endocrine Tumours with Interferon-? and OctreotideActa Oncologica, 1991
- In vitro and in vivo inhibition of human small cell lung carcinoma (NCl-H69) growth by a somatostatin analogueBiochemical and Biophysical Research Communications, 1988
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeNew England Journal of Medicine, 1983